sotatercept

FDA gives Merck priority review for blood vessel disorder therapy sotatercept
FDA gives Merck priority review for blood vessel disorder therapy sotatercept
Medical Marketing and Media
Merck
PAH
sotatercept
FDA
Flag link:
Merck keeps pumping up sotatercept, posting fresh data ahead of FDA approval ruling
Merck keeps pumping up sotatercept, posting fresh data ahead of FDA approval ruling
Fierce Biotech
Merck
sotatercept
FDA
cardiovascular disease
Flag link:
The 10 highest value R&D projects in biopharma
The 10 highest value R&D projects in biopharma
Fierce Biotech
R&D
biotech
Merck
sotatercept
Daiichi Sankyo
AstraZeneca
Dato-DXd
Novo Nordisk
CagriSema
Eli Lilly
donanemab
Karuna Therapeutics
Zai Lab
KarXT
Moderna Therapeutics
mRNA-1647
Novartis
iptacopan
Madrigal Pharmaceuticals
resmetirom
Cytokinetics
aficamten
Roche
Chugai
tiragolumab
Flag link:
Gossamer could put pressure on Merck
Gossamer could put pressure on Merck
EP Vantage
Merck
Gossamer Bio
PAH
sotatercept
United Therapeutics
ralinepag
Flag link:
Sotatercept- the breakthrough PAH has been waiting for?
Sotatercept- the breakthrough PAH has been waiting for?
Clinical Trials Arena
Merck
sotatercept
Acceleron
PAH
Flag link:
Is Merck Moving Toward Another Blockbuster Drug Launch?
Is Merck Moving Toward Another Blockbuster Drug Launch?
Motley Fool
Merck
sotatercept
PAH
Flag link:
Merck nails phase 3 sotatercept win, making good on its $11.5B Acceleron buy
Merck nails phase 3 sotatercept win, making good on its $11.5B Acceleron buy
Fierce Biotech
Merck
Acceleron
clinical trials
sotatercept
PAH
pulmonary arterial hypertension
Flag link:
Merck & Co justifies paying up for Acceleron
Merck & Co justifies paying up for Acceleron
EP Vantage
Merck
Accleron
M&A
sotatercept
Reblozyl
PAH
Flag link:
Merck emerges as lead bidder in potential Acceleron buyout with deal possible this week — report
Merck emerges as lead bidder in potential Acceleron buyout with deal possible this week — report
Endpoints
Merck
Acceleron
M&A
PAH
sotatercept
Flag link:
Acceleron uncorks more mid-stage data for PAH drug sotatercept as part of the drug's resurrection campaign
Acceleron uncorks more mid-stage data for PAH drug sotatercept as part of the drug's resurrection campaign
Endpoints
Acceleron
sotatercept
PAH
Flag link:
Acceleron's PAH drug gets the FDA's red carpet treatment with breakthrough status
Acceleron's PAH drug gets the FDA's red carpet treatment with breakthrough status
Endpoints
Acceleron
PAH
FDA
breakthrough therapy
sotatercept
Flag link:
Acceleron’s post-Reblozyl plan comes together
Acceleron’s post-Reblozyl plan comes together
EP Vantage
Acceleron
sotatercept
PAH
JNJ
Bellerophon Therapeutics
United Therapeutics
Vivus
Arena
Novartis
Flag link:
Acceleron Shares Surge as Its Hypertension Drug Meets Trial Endpoints
Acceleron Shares Surge as Its Hypertension Drug Meets Trial Endpoints
Motley Fool
Acceleron
PAH
clinical trials
sotatercept
Flag link:
Acceleron gets FDA orphan drug designation for sotatercept in pulmonary arterial hypertension
Acceleron gets FDA orphan drug designation for sotatercept in pulmonary arterial hypertension
Pharmaceutical Business Review
Acceleron
orphan drugs
sotatercept
PAH
Flag link:
Celgene anemias treatment granted FDA orphan designation
Celgene anemias treatment granted FDA orphan designation
Yahoo/Fly on the Wall
FDA
Celgene
anemia
sotatercept
Flag link:
Acceleron, Celgene Vs. Amgen In The Anemia Drug Race
Acceleron, Celgene Vs. Amgen In The Anemia Drug Race
Seeking Alpha
Amgen
Acceleron
Celgene
anemia
sotatercept
ACE-536
Flag link: